AMITA SHUKLA  |  Innovator  |  Entrepreneur  |  Speaker  Author

Twitter LinkedIn Facebook

Amita ShuklaAmita Shukla is an innovator and entrepreneur focused on creating transformative innovations for human health, well-being, and potential. She is the founder and CEO of Vitamita and the author of Enduring Edge: Transforming How We Think, Create and Change. Amita regularly advises companies and organizations and has been invited to present over 100 keynotes, lectures, and workshops to innovators, entrepreneurs, and leaders in industry, academia, and government. Her work and talks focus on mastering mindset agility for individual, team, organizational, and societal transformation.

Previously, she spent close to nine years at New Enterprise Associates, one of the world’s largest and most active venture capital firms with over $20 billion in total capital, where she evaluated cutting-edge medical innovations, invested in healthcare startups, and worked with leading scientists, physicians, and entrepreneurs to build world-class companies. Earlier, she was vice president of AmiKa Corp., a biomedical technology company where she helped develop and market novel research tools—for which she holds 10 issued patents—until its acquisition by Harvard Bioscience. Previously, she founded two startups and was a healthcare analyst at Merrill Lynch. Previously, she founded two startups and was a healthcare analyst at Merrill Lynch. She has written about innovation for publications such as the MIT Technology Review.

In 2018, Amita became an Adjunct Lecturer at Johns Hopkins to teach a graduate course on leadership, for which Enduring Edge has been a required textbook since 2014. Previously, she served as a Mentor-in-Residence to help Hopkins’ researchers realize the potential of their groundbreaking discoveries. In 2010, Governor Martin O’Malley appointed Amita to the board of Maryland’s Technology Development Corporation (TEDCO), a leader in seed/early-stage investing. She was reappointed by Governor Larry Hogan in 2015, and is currently its longest-serving board member. Amita holds a BA in biochemistry from Harvard, where she was a Senior Editor at the Harvard Crimson, and an MBA from Stanford, where she led a team that won the university-wide annual business plan competition for a novel cardiovascular device.

Amita has received training as a coach and is certified as a yoga teacher. Her passion for human well-being traces back to high school, where she received first place at the International Science and Engineering Fair for her research on an Indian medicinal plant for preventing gum disease.

Learn about Amita’s Upcoming (and prior) Talks, Keynotes, and Workshops

Selected Additional Positions:

• President, Stanford Graduate School of Business (GSB) Washington DC Chapter (2015-present)
• Co-founder of the Stanford GSB DC Salons (2016-present)
• Life Science Council Member, Springboard Enterprises (2012-present)
• Inaugural Pharmapreneur-in-Residence at the University of Maryland School of Pharmacy (2017-2018)
• Fish & Richardson FISHstep Review Committee Member (2015-2017)
• AccelerateDC Mentor (2015-2017)
• Johns Hopkins Medicine Alliance for Science and Technology Development (2007-2015)
• TiE DC: Board of Directors (2008); Charter Member (2007-08)

Selected Writings & Publications:

Articles Featuring Amita:

In Conversation with Amita Shukla, Founder and CEO of Vitamita BioBuzz
“The School of Pharmacy’s Revolution: Pharmapreneurism – Meet Pharmapreneur-inResidence, Amita Shukla” Capsule Magazine, Summer 2017
“Advice to mHealth entrepreneurs? Change behaviors” mHealthNews
“14 #mHealth13 Tweets for mHealth Entrepreneurs” mHealthNews: “The start of the 2013 mHealth Summit has been jam packed with advice for mhealth startups and investors. From Amita Shukla’s tips for budding innovators to the insights shared by renowned entrepreneurs and investors Steve Case and Esther Dyson, here’s some of our favorite soundbites captured via #mHealth13.”
“Three Women Who Make Me Optimistic About the Future of Healthcare” MedCityNews
“Is Entrepreneurialism Genetic?” Venture Capital Journal